GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clever Leaves Holdings Inc (NAS:CLVR) » Definitions » 3-Year EBITDA Growth Rate

Clever Leaves Holdings (Clever Leaves Holdings) 3-Year EBITDA Growth Rate : 39.90% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Clever Leaves Holdings 3-Year EBITDA Growth Rate?

Clever Leaves Holdings's EBITDA per Share for the three months ended in Dec. 2023 was $-2.65.

During the past 3 years, the average EBITDA Per Share Growth Rate was 39.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Clever Leaves Holdings was 39.90% per year. The lowest was 16.40% per year. And the median was 28.15% per year.


Competitive Comparison of Clever Leaves Holdings's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Clever Leaves Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clever Leaves Holdings's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clever Leaves Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Clever Leaves Holdings's 3-Year EBITDA Growth Rate falls into.



Clever Leaves Holdings 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Clever Leaves Holdings  (NAS:CLVR) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Clever Leaves Holdings 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Clever Leaves Holdings's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Clever Leaves Holdings (Clever Leaves Holdings) Business Description

Traded in Other Exchanges
N/A
Address
19-B Parque Industrial Tibitoc, Tocancipá, Cundinamarca, Bodega, Colombia, BC, CAN
Clever Leaves Holdings Inc is a producer of pharmaceutical and consumer cannabis brands. The company operates and has investments in Canada, Colombia, Germany, Portugal, and the United States. The company operates in two reportable segments, 1. The Cannabinoid operating segment: is comprised of the Company's cultivation, extraction, and commercialization of cannabinoid products. 2. Non-Cannabinoid operating segment is engaged in the business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements.
Executives
Andres Fajardo director, officer: President CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
Julian Wilches officer: Chief Regulatory Officer CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
Hague Henry R Iii officer: Chief Financial Officer 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
Gary M Julien director ONE LANDMARK SQUARE, 22ND FLOOR, STAMFORD CT 06901
William Muecke director C/O CLEVER LEAVES HOLDINGS, 6501 CONGRESS AVE, SUITE 240, BOCA RATON FL 33487
David Kastin officer: General Counsel C/O VITAMIN SHOPPE, INC., SECAUCUS NJ 07094
Kyle Detwiler director, officer: Chief Executive Officer CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
George J Schultze 10 percent owner C/O SCHULTZE ASSET MANAGEMENT, LLC, 3000 WESTCHESTER AVENUE, PURCHASE NY 10577
Elisabeth H Demarse director CREDITCARDS.COM, 13809 RESEARCH BOULEVARD, SUITE 906, AUSTIN TX 78750
Etienne H. Deffarges director ACCRETIVE HEALTH, INC., 401 NORTH MICHIGAN AVENUE, SUITE 2700, CHICAGO IL 60611
Schultze Special Purpose Acquisition Sponsor, Llc 10 percent owner 800 WESTCHESTER AVENUE, SUITE 632, RYE BROOK NY 10573
Amit Pandey officer: Interim CFO CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017